Literature DB >> 15531506

Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells.

Jung-Hye Choi1, Kyung-Chul Choi, Nelly Auersperg, Peter C K Leung.   

Abstract

It has been previously demonstrated that human ovarian cancer cells express FSH receptor (FSHR). However, whether FSHR plays a role in ovarian cancer development is still ambiguous. To investigate the role of FSHR in tumor progression, we overexpressed the receptor in SV40 Tag immortalized ovarian surface epithelium (OSE) cell lines (IOSE-80PC, a postcrisis line, and IOSE-398), which are preneoplastic and nontumorigenic. We compared the expression levels of several selected oncogenes in nontransfected (80PC), vector-transfected (80PCV), FSHR-transfected IOSE (80PCF) cells, and established ovarian cancer cell lines (OVCAR-3 and SKOV-3). Significantly increased protein levels of epithelial growth factor receptor, HER-2/neu, and c-Myc, but not K-Ras, were observed in FSHR-overexpressing 80PCF cells when compared with 80PCV cells. Constitutive phosphorylation of ERK1/2 was augmented in 80PCF cells, whereas phosphorylation of the other MAPK including p38 and Jun N-terminal kinase was unchanged. Considerable constitutive phosphorylation of ERK1/2 was also observed in OVCAR-3 and SKOV-3 cell lines when compared with 80PCV. More importantly, 80PCF cells grew more rapidly than 80PC and 80PCV cells. In conclusion, we have demonstrated that FSHR was highly expressed in OVCAR-3 and 80PCF cells transfected with FSHR overexpression vector. The 80PCF cell line showed increased levels of epithelial growth factor receptor, HER-2/neu, and c-myc and constitutive activation of ERK1/2. The rate of proliferation of the 80PCF cells was increased, compared with control cell lines. These results suggest that the overexpression of FSHR may be associated with enhanced levels of potential oncogenic pathways and increased proliferation in preneoplastic ovarian surface epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531506     DOI: 10.1210/jc.2004-0044

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  32 in total

1.  Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.

Authors:  Alfredo Perales-Puchalt; Nikolaos Svoronos; Melanie R Rutkowski; Michael J Allegrezza; Amelia J Tesone; Kyle K Payne; Jayamanna Wickramasinghe; Jenny M Nguyen; Shane W O'Brien; Kiranmai Gumireddy; Qihong Huang; Mark G Cadungog; Denise C Connolly; Julia Tchou; Tyler J Curiel; Jose R Conejo-Garcia
Journal:  Clin Cancer Res       Date:  2016-07-19       Impact factor: 12.531

Review 2.  Possible role of Moringa oleifera Lam. root in epithelial ovarian cancer.

Authors:  Chinmoy K Bose
Journal:  MedGenMed       Date:  2007-02-06

3.  The Asn680Ser polymorphism of the follicle stimulating hormone receptor gene and ovarian cancer risk: a meta-analysis.

Authors:  Xue Qin; Liping Ma; Shi Yang; Jianyang Zhao; Siyuan Chen; Yantong Xie; Jian Wang; Taijie Li; Yu He; Qiliu Peng; Yan Deng; Shan Li; Aiping Qin
Journal:  J Assist Reprod Genet       Date:  2014-06       Impact factor: 3.412

Review 4.  Microenvironment and pathogenesis of epithelial ovarian cancer.

Authors:  Antonio F Saad; Wei Hu; Anil K Sood
Journal:  Horm Cancer       Date:  2010-12       Impact factor: 3.869

Review 5.  Current concepts of follicle-stimulating hormone receptor gene regulation.

Authors:  Jitu W George; Elizabeth A Dille; Leslie L Heckert
Journal:  Biol Reprod       Date:  2010-08-25       Impact factor: 4.285

6.  Development and characterization of high affinity leptins and leptin antagonists.

Authors:  Michal Shpilman; Leonora Niv-Spector; Meirav Katz; Chen Varol; Gili Solomon; Michal Ayalon-Soffer; Eric Boder; Zamir Halpern; Eran Elinav; Arieh Gertler
Journal:  J Biol Chem       Date:  2010-11-30       Impact factor: 5.157

7.  ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.

Authors:  Bin Guan; Tian-Li Wang; Ie-Ming Shih
Journal:  Cancer Res       Date:  2011-09-07       Impact factor: 12.701

8.  Ascites analysis by a microfluidic chip allows tumor-cell profiling.

Authors:  Vanessa M Peterson; Cesar M Castro; Jaehoon Chung; Nathan C Miller; Adeeti V Ullal; Maria D Castano; Richard T Penson; Hakho Lee; Michael J Birrer; Ralph Weissleder
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

9.  Alterations in gene expression in human mesothelial cells correlate with mineral pathogenicity.

Authors:  Arti Shukla; Maximilian B MacPherson; Jedd Hillegass; Maria E Ramos-Nino; Vlada Alexeeva; Pamela M Vacek; Jeffrey P Bond; Harvey I Pass; Chad Steele; Brooke T Mossman
Journal:  Am J Respir Cell Mol Biol       Date:  2008-12-18       Impact factor: 6.914

10.  Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway.

Authors:  J Chen; M Bai; C Ning; B Xie; J Zhang; H Liao; J Xiong; X Tao; D Yan; X Xi; X Chen; Y Yu; R C Bast; Z Zhang; Y Feng; W Zheng
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.